BTG plc (LON:BTG) has been assigned an average recommendation of “Buy” from the nine analysts that are covering the company. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is GBX 762 ($9.91).

A number of research analysts recently weighed in on BTG shares. Jefferies Group LLC dropped their price target on BTG plc from GBX 860 ($11.19) to GBX 775 ($10.08) and set a “buy” rating on the stock in a research note on Tuesday, January 24th. Peel Hunt started coverage on BTG plc in a research note on Wednesday, January 25th. They set a “hold” rating and a GBX 630 ($8.20) price target on the stock. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 900 ($11.71) price target on shares of BTG plc in a research note on Wednesday, January 25th. Deutsche Bank AG dropped their price target on BTG plc from GBX 800 ($10.41) to GBX 775 ($10.08) and set a “buy” rating on the stock in a research note on Thursday, January 26th. Finally, Panmure Gordon reaffirmed a “buy” rating and set a GBX 737 ($9.59) price target on shares of BTG plc in a research note on Thursday, January 26th.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/05/23/btg-plc-btg-receives-average-rating-of-buy-from-brokerages.html.

Shares of BTG plc (LON:BTG) opened at 645.00 on Tuesday. The firm’s market cap is GBX 2.48 billion. BTG plc has a 52-week low of GBX 528.36 and a 52-week high of GBX 739.50. The stock’s 50 day moving average price is GBX 659.07 and its 200-day moving average price is GBX 600.02.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

12 Month Chart for LON:BTG

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.